Effect of Roxadustat on Cardiometabolism
- Conditions
- Risk factors of cardiovascular disease, metabolic syndromeTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-508183-29-00
- Lead Sponsor
- Pohjois-Pohjanmaan hyvinvointialue
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Body mass index over 20 kg/m2 and body weight below 100 kg, Good general health based upon the results of the medical history, laboratory tests, physical examination, and 12-lead ECG as assessed by the investigator
Regular medication (not including hormonal intrauterine device), Fear of pricking and previous difficult blood sampling, Significant diseases, Systolic blood pressure over 150 mmHg, Hemoglobin levels above Finnish reference values, Pregnancy or breast feeding, WOCBP not using very potent contraception during study periods and one week after, Previous venous thrombosis or previous convulsions, Family history of significant venous thrombosis, Familial galactose intolerance, total lactase deficiency or absorbtion deficiency of glucose and galactose, Allergy to peanut or soy, Unable to speak Finnish, Significant surgery 6 months before trial, Participation in another clinical trial one month before beginning of the trial, Abuse of alcohol or medicines or use of drugs
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method